Pivekimab sunirine is a medicine for a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm. It's given as an infusion into a vein. It works by carrying a cancer-killing drug straight to cancer cells that have a certain marker on them.
Every report comes from a Lived member, sent anonymously.
Have you tried Decnupaz (Pivekimab Sunirine) for Blastic Plasmacytoid Dendritic Cell Neoplasm?
Pivekimab sunirine, sold as Decnupaz, is a targeted cancer medicine approved in the US in 2026 for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare, aggressive blood cancer. It very often shows up in the skin, and it can also involve the bone marrow, the bloodstream and the lymph nodes. Decnupaz is used both for people who are newly diagnosed and for people whose BPDCN has come back or did not respond to earlier treatment. It is one of two targeted medicines for this cancer. The other, tagraxofusp (Elzonris), aims at the same marker on the cancer cells but works differently, carries different risks, and is also approved for children 2 and older. Decnupaz is approved only for adults. For many people, the larger aim of treatment is to bring the cancer into remission so that a stem cell transplant becomes possible, because a successful transplant is what most strongly shapes long-term survival in BPDCN.
Decnupaz is an antibody-drug conjugate: a lab-made antibody joined to a powerful cancer-killing drug. The antibody is built to find CD123, a protein that BPDCN cells carry on their surface (CD123 is part of the receptor for interleukin-3, a signal that helps blood cells grow). Once the antibody latches on, the cell draws the whole package inside and breaks it down, which frees the attached drug. That drug damages the cell's DNA, so the cell can no longer divide and dies. Delivering the drug this way concentrates it on cells carrying CD123 instead of spreading it evenly through the body, as traditional chemotherapy does. It does not spare healthy tissue entirely, which is why blood counts and the liver still need close watching.
Decnupaz is given in a hospital or infusion center as an infusion into a vein, usually over about 15 to 30 minutes, once every three weeks. The dose is calculated from body weight. Treatment continues in three-week cycles until the cancer progresses, side effects become too hard to manage, or the plan moves on, for example to a stem cell transplant. Preparation starts the day before each infusion, when people take a steroid (usually dexamethasone). Shortly before the infusion they receive another steroid dose, an antihistamine (diphenhydramine) and a fever reducer (acetaminophen). These lower the chance and severity of an infusion reaction, so it matters to take the day-before dose as instructed. The first infusion is given more slowly, and the team watches for a reaction for at least four hours afterward; later infusions need at least an hour of observation. Blood tests that check the liver are done before every dose. If they are raised, the dose is delayed until they settle.
The most common side effects are swelling from fluid build-up (edema), tiredness, muscle and joint aches, bleeding or easy bruising, nausea and diarrhea. Swelling affects about half of people and can become serious, sometimes with fluid collecting around the lungs or heart. Contact the care team about new swelling in the legs or face, quick weight gain or shortness of breath, so they can treat it and decide whether to delay the next dose. About a quarter of people have an infusion reaction, most often during the first infusion. Signs include chills, fever, flushing, nausea, chest discomfort, a racing heart and trouble breathing. Tell the infusion staff straight away if you feel any of these, because they can pause or slow the infusion and treat the reaction. If they start after you get home, call the care team right away. Blood counts often fall, especially infection-fighting white cells and platelets, so infections and bleeding are among the more serious problems seen in the main study. In that study about half of people had at least one serious side effect. The care team will explain what to do about a fever and will check blood counts regularly.
Decnupaz carries the FDA's most serious (boxed) warning, for liver injury that includes veno-occlusive disease (VOD), a condition in which small veins inside the liver become blocked. VOD can be severe or fatal. In the main study it occurred in about 2% of people during treatment, but in about a quarter of those who later had a stem cell transplant (5 of 19), two of whom died. Because transplant is often the goal, the transplant team needs to know you received Decnupaz. Call your care team right away for yellowing of the skin or eyes, dark urine, rapid weight gain, or pain or swelling in the belly. If VOD develops, Decnupaz is stopped for good. It is generally avoided in people with moderate or severe liver impairment. The infusion contains sodium metabisulfite, a sulfite preservative that can trigger allergic reactions and asthma-type attacks in sensitive people, more often in people with asthma. Tell the team about any sulfite sensitivity, and get immediate medical care for wheezing, trouble breathing or other signs of a severe allergic reaction. Medicines that strongly or moderately block CYP3A, a liver enzyme that clears the attached cancer drug, can raise its levels and make side effects more likely. The team usually monitors more closely rather than banning these combinations, so share a complete list of prescriptions, over-the-counter medicines and supplements. Decnupaz can harm a developing baby. A pregnancy test is done before starting. Women who could become pregnant should use effective birth control during treatment and for 7 months after the last dose, and men with a partner who could become pregnant should do so for 4 months after. Breastfeeding is not advised during treatment or for 1 month afterward. The medicine may also reduce fertility in both men and women, which is worth raising before treatment starts if future children matter.
Treatment means an infusion visit every three weeks, with liver blood tests before each dose and premedication the day before. When the medicine works, it tends to show fairly early: newly diagnosed people in the main study who responded did so after a median of about two months. In that study, about 7 in 10 newly diagnosed people (23 of 33) reached complete remission (no detectable cancer) or clinical complete remission (the same, apart from leftover skin marks that are not active cancer). For people whose BPDCN had returned or resisted earlier treatment, the rate was much lower, about 1 in 6 (8 of 51). Remissions lasted a median of roughly nine to ten months, so for people who are able, a stem cell transplant is often planned as the next step. About 4 in 10 of the newly diagnosed group went on to one. These results come from a single study with no comparison group, and Decnupaz has not been compared directly with tagraxofusp. The choice between them depends on liver health, other medical conditions, transplant plans and which risks matter most for the person. Neither medicine has been shown to protect the brain and spinal cord, where BPDCN can spread, so the team may test the spinal fluid and give separate treatment there. Many people in the study were in their 70s or 80s, and older age did not change how safe or effective the medicine was.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Decnupaz (Pivekimab Sunirine), what you've noticed, or ask the community a question.